510 related articles for article (PubMed ID: 19537373)
1. Treatment of facial lipoatrophy via autologous fat transfer.
Cohen G; Treherne A
J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
[TBL] [Abstract][Full Text] [Related]
2. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
[TBL] [Abstract][Full Text] [Related]
3. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
[TBL] [Abstract][Full Text] [Related]
4. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
[TBL] [Abstract][Full Text] [Related]
5. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.
Guaraldi G; De Fazio D; Orlando G; Murri R; Wu A; Guaraldi P; Esposito R
Clin Infect Dis; 2005 Jan; 40(2):e13-5. PubMed ID: 15655734
[TBL] [Abstract][Full Text] [Related]
6. Treatment of facial lipoatrophy in HIV-infected patients.
Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
[TBL] [Abstract][Full Text] [Related]
7. Approaches to treatment of HIV facial lipoatrophy.
Jones D
Skin Therapy Lett; 2005 Nov; 10(9):5-7. PubMed ID: 16292459
[TBL] [Abstract][Full Text] [Related]
8. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
9. A comparison of lipoatrophy and aging: volume deficits in the face.
Coleman S; Saboeiro A; Sengelmann R
Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
[TBL] [Abstract][Full Text] [Related]
10. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic hemi-facial lipoatrophy treated with autologous fat transfer.
Liu SW; Cohen GF
J Cosmet Dermatol; 2010 Sep; 9(3):226-9. PubMed ID: 20883296
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
[TBL] [Abstract][Full Text] [Related]
14. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
Parruti G; Toro GM
BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
[TBL] [Abstract][Full Text] [Related]
15. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
16. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R
Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569
[TBL] [Abstract][Full Text] [Related]
17. Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
Shuck J; Iorio ML; Hung R; Davison SP
Plast Reconstr Surg; 2013 Mar; 131(3):499-506. PubMed ID: 23142937
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
Phillips DR; Hay P
J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
[TBL] [Abstract][Full Text] [Related]
19. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
Mallewa JE; Wilkins E; Vilar J; Mallewa M; Doran D; Back D; Pirmohamed M
J Antimicrob Chemother; 2008 Oct; 62(4):648-60. PubMed ID: 18565973
[TBL] [Abstract][Full Text] [Related]
20. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Ramon Y; Fodor L; Ullmann Y
Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
